









Markets
/
Stocks
/
nasdaq-sabs
/

SAB Biotherapeutics Inc

SABS

4.170USD

+0.190+4.77%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

198.05MMarket Cap

LossP/E TTM



SAB Biotherapeutics Inc

4.170

+0.190+4.77%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of SAB Biotherapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

SAB Biotherapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 87 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.38.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

SAB Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

87 / 392

Overall Ranking

213 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

SAB Biotherapeutics Inc Highlights

StrengthsRisks

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.32M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.32M.

Undervalued

The company’s latest PE is -8.36, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 29.75M shares, increasing 46.68% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 80.84K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.75.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.375

Target Price

+135.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of SAB Biotherapeutics Inc is 6.23, ranking 278 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.23

Change



Financials

6.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.41

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

SAB Biotherapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of SAB Biotherapeutics Inc is 8.54, ranking 38 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.36, which is -96.41% below the recent high of -0.30 and -6.72% above the recent low of -8.92.

Score

Industry at a Glance

Previous score

8.54

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 87/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of SAB Biotherapeutics Inc is 8.75, ranking 61 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 14.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.375

Target Price

+135.55%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

SAB Biotherapeutics Inc

SABS

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of SAB Biotherapeutics Inc is 7.13, ranking 100 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.76 and the support level at 3.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.92

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.035

Neutral

RSI(14)

53.465

Neutral

STOCH(KDJ)(9,3,3)

36.835

Neutral

ATR(14)

0.302

Low Volatility

CCI(14)

-64.944

Neutral

Williams %R

54.839

Neutral

TRIX(12,20)

0.528

Sell

StochRSI(14)

30.018

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

4.242

Sell

MA10

4.284

Sell

MA20

4.113

Buy

MA50

3.936

Buy

MA100

3.367

Buy

MA200

2.700

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of SAB Biotherapeutics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.49%, representing a quarter-over-quarter decrease of 22.74%. The largest institutional shareholder is The Vanguard, holding a total of 1.85M shares, representing 3.88% of shares outstanding, with 29.87% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Vivo Capital, LLC

11.42M

Commodore Capital LP

4.40M

Vivo Opportunity Fund Holdings, L.P.

4.40M

RA Capital Management, LP

4.40M

Woodline Partners LP

2.85M

Sessa Capital

2.20M

+379.53%

The Vanguard Group, Inc.

Star Investors

365.75K

+29.53%

BVF Partners L.P.

932.70K

+1.62%

Sphera Funds Management Ltd.

566.39K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of SAB Biotherapeutics Inc is 2.74, ranking 204 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.